Gene therapy Archives

More News! 28 Oct 2019

UK Company Synthesizes Long DNA Molecules with 85% Accuracy

The UK biotech Camena Bioscience has proven it can synthesize long DNA molecules with more accuracy than traditional chemical synthesis. Camena tested its technology’s ability to accurately synthesize DNA molecules with a length of 300 nucleotides — the building blocks of DNA. Using Camena’s technology, 85% of the synthesized DNA molecules were accurate to the […]

October 28, 2019 - 2 minutesmins - By Jonathan Smith

gene therapy cell therapy advanced therapy 4BIO

News and Trends 9 Sep 2019

4BIO Capital Raises €45M Fund to Invest in Advanced Therapies

The London-based life sciences investor 4BIO Capital has raised €45M in the first close of a fund to nurture companies developing advanced therapies such as gene and cell therapies. This is the first closing of 4BIO’s second fund, called 4BIO Ventures II, which is expected to total €136M ($150M) by late 2020. The fund will […]

September 9, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 5 Sep 2019

Orchard’s Gene Therapy Improves Children’s Motor Ability

Orchard Therapeutics’ gene therapy for metachromatic leukodystrophy (MLD) resulted in motor ability improvements more than six times over the target endpoint, according to data released at a recent symposium. “Metachromatic leukodystrophy is a rare disease that affects the brain,” explained Mark Rothera, CEO of Orchard Therapeutics. “Kids born with MLD lose motor function very fast […]

September 5, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Sep 2019

Gyroscope Targets Age-Related Blindness with €55M Series B

UK gene therapy biotech Gyroscope Therapeutics has secured €55.4M in Series B funding to target age-related macular degeneration. Life sciences investor Syncona, which is backed by the UK’s Wellcome Trust, continued its support of the company contributing €52.7M to the round. This brings its total investment in Gyroscope to €90M since the biotech was founded […]

September 3, 2019 - 2 minutesmins - By Helen Albert

News and Trends 13 Aug 2019

AskBio Acquires Scottish Biotech to Make Gene Therapies More Precise

The US company AskBio has acquired the Edinburgh-based Synpromics to pool their gene therapy technologies and produce inducible gene therapies that target particular organs or cells. AskBio specializes in developing viral vectors that carry gene therapies into cells, such as adeno-associated virus, whereas Synpromics develops DNA sequences called promoters that drive the expression of gene […]

August 13, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 14 Jun 2019

First Gene Therapy for Beta Thalassemia Will Cost Over €1.5M

Zynteglo, a gene therapy developed by the US company bluebird bio for the treatment of beta-thalassemia, will cost European healthcare systems more than €1.5M per patient. Following the approval of the treatment earlier this month, bluebird bio has now released the pricing plan of Zynteglo. Healthcare systems in Europe will need to pay €315,000 upfront, […]

June 14, 2019 - 1 minutemin - By Jonathan Smith

bluebird bio gene therapy beta thalassemia

News and Trends 4 Jun 2019

First Gene Therapy for Beta Thalassemia Approved in Europe

The US biotech company bluebird bio has obtained EU conditional market approval for a gene therapy that could remove the need for blood transfusions for people with the blood disorder beta-thalassemia. Called Zynteglo, the gene therapy is aimed at treating people with beta-thalassemia who are over 12 years of age and have any but the […]

June 4, 2019 - 3 minutesmins - By Jonathan Smith

gensight gene therapy lhon genetic blindness

News and Trends 29 May 2019

After Unexpected Setback, GenSight Seeks Approval for Blindness Gene Therapy

The French biotech GenSight will apply for regulatory approval for its gene therapy despite the treatment unexpectedly resulting in the improvement of the eyes treated with a placebo in a phase III trial. GenSight is developing a gene therapy designed to treat progressive vision loss caused by the rare genetic condition Leber hereditary optic neuropathy. […]

May 29, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 29 May 2019

€60M Investment to Boost Oxford Biomedica’s Gene and Cell Therapies

The Danish investor Novo Holdings is handing Oxford Biomedica up to €60.6M (£53.5M) to develop gene and cell therapies treating cancer and genetic blindness. The investment will bag Novo Holdings a stake of up to 10.1% in the UK biotech. Oxford Biomedica will use the money to repay a loan totalling €49M ($55M) from the […]

May 29, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 14 May 2019

First Potential Gene Therapy for Hemophilia B Restores Blood Clotting in Phase II

A gene therapy developed by the Dutch biotech uniQure increased the activity of a blood clotting protein enough to stop bleeds in patients with the blood disorder hemophilia B. Hemophilia B is a rare genetic condition in which patients have a mutation in the blood clotting protein factor IX (FIX), reducing its activity below 6% […]

May 14, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 30 Apr 2019

Orchard’s Gene Therapy Shows Potential in Treating Patients with Beta Thalassemia

Patients with the life-threatening blood disorder beta-thalassemia required fewer blood transfusions after receiving a gene therapy developed by the UK company Orchard Therapeutics, with four out of nine no longer depending on transfusions. Beta thalassemia is a genetic disorder that affects hemoglobin, a protein that blood cells use to carry oxygen. In the most severe […]

April 30, 2019 - 3 minutesmins - By Jonathan Smith

Interview 25 Apr 2019

European Biotechnology in 2019 and Beyond: What’s Hot and What’s Not?

We spend a lot of time focusing on specific developments in biotechnology, but sometimes it’s good to take a step back and look at the bigger picture. With this in mind, I asked three experts at our recent Refresh event in Vienna to share what is hot in European biotech right now and what trends […]

April 25, 2019 - 11 minutesmins - By Helen Albert

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us